HER2-negative Breast Cancer Clinical Trials

38 recruiting

HER2-negative Breast Cancer Trials at a Glance

45 actively recruiting trials for her2-negative breast cancer are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Boston, Chicago, and Nashville. Lead sponsors running her2-negative breast cancer studies include Fudan University, Memorial Sloan Kettering Cancer Center, and QuantumLeap Healthcare Collaborative.

Browse her2-negative breast cancer trials by phase

Treatments under study

About HER2-negative Breast Cancer Clinical Trials

Looking for clinical trials for HER2-negative Breast Cancer? There are currently 38 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-negative Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-negative Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 2

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Breast CancerHER2-negative Breast CancerHormone Receptor Positive Tumor+1 more
SOLTI Breast Cancer Research Group96 enrolled15 locationsNCT05982093
Recruiting
Phase 1Phase 2

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619
Recruiting
Phase 1

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

HR+/HER2-negative Breast Cancer
Totus Medicines241 enrolled18 locationsNCT05683418
Recruiting
Not Applicable

A Study of the TheraBionic P1 Device in Breast Cancer

HER2-negative Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Barbara Ann Karmanos Cancer Institute24 enrolled8 locationsNCT07218432
Recruiting
Phase 1Phase 2

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Sarah Sammons, MD65 enrolled1 locationNCT07198724
Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer

Breast CancerHER2-negative Breast Cancer
Memorial Sloan Kettering Cancer Center176 enrolled7 locationsNCT07483307
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

HER2-negative Breast CancerBreast Cancer (Early Breast Cancer)Breast Cancer Survivors+2 more
Assistance Publique - Hôpitaux de Paris1,000 enrolled1 locationNCT07379918
Recruiting
Phase 1Phase 2

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

HER2-negative Breast CancerEarly Breast CancerHormone Receptor Positive Tumor
Institute of Oncology Ljubljana319 enrolled1 locationNCT06650423
Recruiting
Phase 3

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
West German Study Group250 enrolled7 locationsNCT07281833
Recruiting
Not Applicable

NearWave Optical Molecular Monitoring

Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+2 more
Indiana University15 enrolled1 locationNCT06744465
Recruiting
Phase 1

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+3 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

HER2-negative Breast Cancer
Mayo Clinic100 enrolled1 locationNCT06388122
Recruiting
Phase 2

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer
University of Wisconsin, Madison13 enrolled1 locationNCT04573231
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticPancreatic CancerHER2-negative Breast Cancer+9 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

HER2-negative Breast Cancer
University of California, San Francisco100 enrolled1 locationNCT06774027
Recruiting
Phase 1

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

HER2-negative Breast CancerBreast Cancer Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute18 enrolled1 locationNCT06691035
Recruiting
Phase 2

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

HER2-negative Breast Cancer Patients With Brain Metastases
Biostar Pharma, Inc.120 enrolled17 locationsNCT06764940